Navigation Links
EpiCept Provides Update on Clinical and Regulatory Progress with Ceplene(TM) and EpiCept(TM) NP-1 Cream
Date:1/22/2008

ed NK-cells and T-cells.

About EpiCept NP-1

EpiCept NP-1 is a patented topical cream formulation of two FDA- approved drugs, 4% amitriptyline and 2% ketamine, and is intended to provide long-term relief from the pain of peripheral neuropathies. Peripheral neuropathies are medical conditions caused by damage to the nerves in the peripheral nervous system. The peripheral nervous system includes nerves that run from the brain and spinal cord to the rest of the body. It is estimated that these conditions affect more than 15 million people in the U.S. and is associated with conditions that injure peripheral nerves, including herpes zoster, or shingles, diabetes, chemotherapy, HIV and other diseases.

About EpiCept Corporation

EpiCept is focused on unmet needs in the treatment of pain and cancer. The Company's broad portfolio of pharmaceutical product candidates includes several pain therapies in clinical development and a lead oncology compound for AML with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound is approaching a decision in Europe. In addition, EpiCept's ASAP technology, a proprietary live cell high- throughput caspase-3 screening technology, can efficiently identify new cancer drug candidates and molecular targets that selectively induce apoptosis in cancer cells. Two oncology drug candidates currently in clinical development that were discovered using this technology have also been shown to act as vascular disruption agents in a variety of solid tumors.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statement
'/>"/>

SOURCE EpiCept Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EpiCept Announces Successful Completion of Enrollment for Phase I Trial of EPC2407
2. EpiCept Reports Regulatory Progress on Ceplene(TM)
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. DuPont Provides Technology for Washington Hospital Centers Emergency Department
5. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
6. ImaRx Provides Update on TUCSON Phase I/II Clinical Trial in Acute Ischemic Stroke
7. Progen Provides Update on Phase 3 Clinical Program for PI-88 in Liver Cancer
8. IDM Pharma Provides Update of Product Pipeline and Announces Plans to Evaluate Strategic Alternatives for the Company
9. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
10. Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery
11. Replidyne Provides Strategic Update

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... Nov. 20 ,, Reportlinker.com an...able in its catalogue. ,, Global Markets for B...rtlinker.com/p0164741/Global-Markets-for-Breast-Bi...tm_medium=pr&utm_campaign=prnewswire ,, T...es the spring loaded core needle market and vacuum...
(Date:11/20/2009)...v. 20 Biotel Inc. (OTC B...st quarter ended September 30, 2009 with net earni...venues of $3,263,000. This compares to net earnin...enues of $3,168,000 for the first quarter of last ...s, Biotel President and CEO Steve Springrose said:...
(Date:11/20/2009)... Nov. 20 Smith & N...ased to announce the signing of a technology devel...of Defense that may lead to the creation of a frac... treatment of the limbs of soldiers who sustain ba...dvanced Research Projects Agency (DARPA), the cent...
Breaking Medicine Technology:Reportlinker Adds Global Markets for Breast Biopsy Devices 2009 2Biotel Announced Profitable First Quarter Ended September 30, 2009 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4Emergency Medical Transport By Air Carries Risks 57178 1Emergency Medical Transport By Air Carries Risks 57178 2The Uptake of Novel Therapies Will Drive the Obesity Drug Market to Increase More than Six Fold to Over 243 2 Billion in 2018 57174 1The Uptake of Novel Therapies Will Drive the Obesity Drug Market to Increase More than Six Fold to Over 243 2 Billion in 2018 57174 2The Uptake of Novel Therapies Will Drive the Obesity Drug Market to Increase More than Six Fold to Over 243 2 Billion in 2018 57174 3Former Corporate Whistleblower Says The Informant Movie is Only Part of the Story 57170 1Former Corporate Whistleblower Says The Informant Movie is Only Part of the Story 57170 2Former Corporate Whistleblower Says The Informant Movie is Only Part of the Story 57170 3
...tions at American Association for Cancer Research,.../PRNewswire-FirstCall/ --,Medarex, Inc. today pres...tumor activity from two separate studies exploring...CD19 and anti-CD70,antibody-drug conjugates. CD19 ...dy-drug conjugate approach to cancer therapy. They...
...pril 17, 2007 /PRNewswire/ -- Researchers from the... MI presented,strong evidence today that an antibi... could be effective in eventually treating,certain...revention Program at Karmanos, and,members of his ...that the drug Clioquinol (CQ) appears to have an a...
Other Medicine Technology:Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 2Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 3Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 4Alzheimer's Drug Shows Promise in Fighting Cancer 2
(Date:11/23/2009)... When Ryan Bailey, a leader in his...ame to the leader in Refractive Surgery, Dr. Rajes...cussion regarding his competitive lifestyle, time ...specific eye parameters. Dr. Khanna then performed...s) November 23, 2009 -- Ryan Bailey won a silver m...
(Date:11/23/2009)... Latham & Phillips Southeaster...omers find the new and used ophthalmic instruments...stomers the opportunity to view a large variety of...heastern Division,s new website enables the compan...ive pricing. Because of the variety of products t...
(Date:11/22/2009)...in known to stimulate blood vessel growth has now ...th in the development of polyps that characterize ... by Johns Hopkins researchers suggests. The findin...el therapies to treat this form of the disease, wh...Chronic sinusitis, a constant irritation and swell...
(Date:11/22/2009)...S Nov. 23, 2009 UT Southwestern Medical Center i...nstitutes of Health to share $56 million over five... (ICAC). , The ICAC, which receives funding thr...nfectious Diseases, investigates novel treatments ...ecca Gruchalla, chief of allergy and immunology at...
(Date:11/22/2009)... World Famous Lasik surgeon, Dr. G...y to an ART in his pursuit for vision beyond 20/20...ternational clientel and is widely published in te... Jacksonville, FL (PRWEB) November 22, 2009... has been selected by Goldline Research as one of...
Breaking Medicine News(10 mins):Health News:Olympic Silver Medalist, Men's Water Polo Star Ryan Bailey Strikes Gold 2Health News:Ophthalmic Equipment Distributor, Latham & Phillips SE Division, Unveils Website 2Health News:Ophthalmic Equipment Distributor, Latham & Phillips SE Division, Unveils Website 3Health News:Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 2Health News:Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps 3Health News:UT Southwestern receives continued NIH funding for Inner City Asthma Consortium 2Health News:Dr. Arun Gulani Listed in Forbes Magazine as One of The Leading Laser Eye Surgeons of the United States 2
... ZyDoc Medical Transcription has been awarded a...service to the State of Colorado Department of Hum...ueblo. , Hauppauge, NY (P...or the State of Colorado Department of Human Servi...
... Ross University School of Medicine will add se...Danbury Hospital in Danbury, CT. , ...9-- Ross University School of Medicine is pleased ...ments will be located at Danbury Hospital in Danbu...
...ary Wilson, founding member of the world,s most fa...d of nearly 500 at the Lupus Foundation of Ameri...on Tuesday, May 12, 2009 with her signature flair .../www.newscom.com/cgi-bin/prnh/20090513/DC15633-a ...
...atient Access To Medical Care And Critical Researc...ies Union and the Public Patent Foundation at Benj...suit today charging that patents on two human gene... along the genes, known as BRCA1 and BRCA2, are re...
...Eye Care Centers of America, Inc. (ECCA) announced... of ECCA,s 10-3/4 percent Senior Subordinated Note...counts managed and/or advised by DDJ Capital Manag... consummated on April 14, 2009. , , About Eye C...
...e UC Davis Center for Healthcare Policy and Resear...cervical intraepithelial neoplasia (abnormal cervi...nce of the disease or invasive cervical cancer. Th...ng-term risks of subsequent abnormal cell growth o...
Other Medicine News:Health News:ZyDoc Medical Transcription Wins Colorado Mental Health Institute Contract Award 2Health News:ZyDoc Medical Transcription Wins Colorado Mental Health Institute Contract Award 3Health News:Ross University School of Medicine Expands Clinical Rotations on East Coast 2Health News:Mary Wilson Brings the Crowd to Their Feet at the Sixth Annual Lupus Foundation of America Awards Gala 2Health News:Mary Wilson Brings the Crowd to Their Feet at the Sixth Annual Lupus Foundation of America Awards Gala 3Health News:ACLU Challenges Patents on Breast Cancer Genes 2Health News:ACLU Challenges Patents on Breast Cancer Genes 3Health News:ACLU Challenges Patents on Breast Cancer Genes 4Health News:Women with previous abnormal cervical cells at higher risk for recurrence and invasive cancer 2Health News:Women with previous abnormal cervical cells at higher risk for recurrence and invasive cancer 3
...io-Dot SF (slot format) microfiltration units prov...ucleic acid in solution onto nitrocellulose or Zet...be accommodated by using interchangeable templates...slot format Bio-Dot SF apparatus. Each is availabl...
Dot Blotting Apparatus
...h vacuum stage, porous vacuum plate, reservoir sea...lid, instructions. The Model 785 vacuum blotter q...n agarose gel onto a nylon membrane. Because it ge...leic acid samples can be separated on a gel, trans...
Mini Trans-Blot
Medicine Products: